Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture HoldingsSCNX +1.88%45 Debt-to-Equity is 0.17 as of Jun. 2026, which is 143% above its 10-year median of 0.07. GuruFocus rates SCNX with a GF Score™ of 45/100 and a GF Value™ of $0.52 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 563 Healthcare Providers & Services companies, Scienture Holdings ranks better than 71.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Scienture Holdings's Debt-to-Equity or its related term are showing as below:
SCNX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.35 Med: 0.07 Max: 2.08
Current: 0.17
During the past 13 years, the highest Debt-to-Equity Ratio of Scienture Holdings was 2.08. The lowest was -3.35. And the median was 0.07.
SCNX's Debt-to-Equity is ranked better than 71.94% of 563
companies
in the Healthcare Providers & Services industry
Industry Median: 0.43
vs SCNX: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Scienture Holdings Debt-to-Equity Related Terms
Scienture Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNX vs PMHS, HEWA, BLMH: Debt-to-Equity Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scienture Holdings (SCNX) has a Debt-to-Equity of 0.17 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scienture Holdings and its competitors. This is 143% above median its historical median of 0.07. According to the industry distribution chart, Scienture Holdings ranks #158 out of 563 companies in the Healthcare Providers & Services industry, placing it in the top 28.1%.
Is Scienture Holdings' Debt-to-Equity too high?
Scienture Holdings' current Debt-to-Equity of 0.17 is 143% above median its 10-year median of 0.07. The Healthcare Providers & Services industry median Debt-to-Equity is 0.43. Scienture Holdings' value of 0.17 is 60.5% below this industry median. Based on the distribution chart, Scienture Holdings ranks #158 out of 563 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Scienture Holdings has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Debt-to-Equity compare to PMHS and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #158 out of 563 companies for Debt-to-Equity. This puts Scienture Holdings in the upper half of its industry. The industry median Debt-to-Equity is 0.43. Scienture Holdings' value of 0.17 is 60.5% below this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.43, Scienture Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scienture Holdings's current Debt-to-Equity of 0.17 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scienture Holdings and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scienture Holdings's current Debt-to-Equity is 0.17, which is 143% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.37 — trading 28.1% below its estimated fair value. The current Debt-to-Equity is 0.17, which is 143% above median its 10-year median of 0.07 and 60.5% below the Healthcare Providers & Services industry median of 0.43. Scienture Holdings' overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Debt-to-Equity is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued.
The current stock price of $0.37 is trading 28.1% below its estimated GF Value™ of $0.52.
GuruFocus considers Scienture Holdings to be Modestly Undervalued.
Key valuation signals for SCNX:
Debt-to-Equity: 0.17 (143% above median its 10-year median of 0.07)
GF Value™: $0.52 vs. price of $0.37 (28.1% below fair value)
Industry Position: 60.5% below the Healthcare Providers & Services median (#158 of 563)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
45GF Score
Get the complete analysis for SCNX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
